Cancer of Unknown Origin

Oncology
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Genomic testingN/A2 trials
Active Trials
NCT03301493Completed1,500Est. Nov 2024
NCT02991274Completed897Est. Jun 2018
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Genomic testingN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaGenomic testing
AstraZenecaGenomic testing

Clinical Trials (2)

Total enrollment: 2,397 patients across 2 trials

NCT03301493AstraZenecaGenomic testing

Genomic Testing and Resulting Medical Decisions

Start: Mar 2017Est. completion: Nov 20241,500 patients
N/ACompleted
NCT02991274AstraZenecaGenomic testing

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Start: Jan 2017Est. completion: Jun 2018897 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space